Discover
NVAX
Novavax, Inc.
9.46
2 x 8.10
1 x 11.50
bid
ask
+
0.04
0.42%
2 @ 07:11 AM
9.50 +0.04 (0.42%)
| Ytd | 40.77% | |
| 1y | 39.94% |
9.29
day range
9.64
6.20
52 week range
11.97
| Open | 9.37 | Prev Close | 9.42 | Low | 9.29 | High | 9.64 | Mkt Cap | 1.56B |
| Vol | 4.43M | Avg Vol | 4.74M | EPS | -0.56 | P/E | N/A | Forward P/E | -17.43 |
| Beta | 2.41 | Short Ratio | 9.14 | Inst. Own | 69.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 9.14 | 200-d Avg | 8.52 | 1yr Est | 14.11 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 0 | N/A | 0.19 | 76.00% |
| 2026-02-26 | 2025-12 | 0 | 0.11 | 0.77 | 116.67% |
| 2025-11-06 | 2025-09 | 0 | N/A | 0.46 | 42.59% |
| 2025-08-06 | 2025-06 | 0 | 0.62 | 0.69 | 985.71% |
| 2025-05-08 | 2025-03 | 0.71 | 2.93 | 2.22 | 312.68% |
| 2025-02-27 | 2024-12 | 0 | N/A | 0.24 | 32.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-11 | BTIG | Upgrade | Buy | Buy |
| 2026-05-06 | TD Cowen | Upgrade | Hold | Hold |
| 2026-02-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-01-20 | BTIG | Upgrade | Buy | Buy |
| 2025-11-18 | JP Morgan | Upgrade | Underweight | Underweight |
| 2025-11-10 | B. Riley Securities | Upgrade | Buy | Buy |
Profile
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-17 | ALTON GREGG H | Director | 47.69K | Conversion of Exercise of derivative security |
| 2026-03-02 | CASEY MARK J | Officer | 90.07K | Conversion of Exercise of derivative security |
| 2026-06-17 | DOUGLAS RICHARD H | Director | 73.22K | Conversion of Exercise of derivative security |
| 2026-03-02 | JACOBS JOHN C | Chief Executive Officer | 225.68K | Conversion of Exercise of derivative security |
| 2026-03-05 | KELLY JAMES PATRICK | Chief Financial Officer | 130.60K | Conversion of Exercise of derivative security |
| 2026-06-17 | MOTT DAVID M | Director | 79.77K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Shah Capital Management | 14.85M | 140.43M | 9.03% |
| 2026-03-30 | Blackrock Inc. | 12.84M | 121.51M | 7.81% |
| 2026-03-30 | State Street Corporation | 8.97M | 84.86M | 5.46% |
| 2026-03-30 | Shaw D.E. & Co., Inc. | 7.71M | 72.94M | 4.69% |
| 2026-03-30 | Vanguard Portfolio Management LLC | 7.15M | 67.65M | 4.35% |
| 2026-03-30 | Vanguard Capital Management LLC | 7.13M | 67.45M | 4.34% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 5.17M | 48.88M | 3.14% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5.14M | 48.58M | 3.12% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.75M | 35.51M | 2.28% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 3.53M | 33.41M | 2.15% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 2.10M | 19.87M | 1.28% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.81M | 17.16M | 1.10% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2019-05-10 |